Contents lists available at ScienceDirect

Bioorganic & Medicinal Chemistry Letters

journal homepage: www.elsevier.com/locate/bmcl

Biorganic & Medicinal Chemistry Letters Description Service Reserve Compared Service Reserve Compared Service Reserve

First asymmetric synthesis of CJ-14877 and its enantiomer and their interleukin-1 β inhibitory activities

Yutaka Aoyagi^a, Yoshiyuki Adachi^b, Shunta Akagi^a, Naohito Ohno^b, Koichi Takeya^{a,*}

^a Natural Products and Medicinal Chemistry, School of Pharmacy, Tokyo University of Pharmacy & Life Sciences, 1432-1 Horinouchi, Hachioji, Tokyo 192-0392, Japan ^b Laboratory for Immunopharmacology of Microbial Products, School of Pharmacy, Tokyo University of Pharmacy & Life Sciences, 1432-1 Horinouchi, Hachioji, Tokyo 192-0392, Japan

ARTICLE INFO

Article history: Received 23 January 2009 Revised 17 February 2009 Accepted 18 February 2009 Available online 21 February 2009

Keywords: CJ-14877 Antiinflammatory Interleukin-1β inhibitory activities Suzuki coupling Sharpless asymmetric dihydroxylation

A methyl picolinate derivative having a C₃ unit on C-5, CI-14877 [(+)-1], and its family (2-4) are potent cytokine inhibitors isolated from a fermentation broth of a fungus basidiomycetes (Fig. 1).¹ Isolation of (+)-1 was reported also from a culture filtrate of a fungus, Hirsutella nivea BCC 2594, a pathogen of insects.² These compounds are shown to inhibit lipopolysaccharide (LPS)-induced production of interleukin-1ß without decreasing the leucine uptake.¹ However, the structure–activity relationship is not known yet. To obtain new antiinflammatory drugs of this series, we studied synthesis of (+)-1. We established a facile two step synthesis of (+)-1 and its enantiomer (–)-1, by the synthetic strategy shown in Scheme 1: stereoselective preparation of (+)-1 and its enantiomer (-)-1 by Sharpless asymmetric dihydroxylation³ of compound 5, which may be obtained via *Suzuki* coupling reaction⁴ between (*E*)-prop-1-enylboronic acid with commercially available methyl 5-bromopicolinate (**6**).⁵

The present paper reports detailed procedure of this method. First, the *Suzuki* coupling reaction of **6** with (*E*)-prop-1-enylboronic acid (**7**) was carried out under several reaction conditions (Table 1). A mixture of **6** and **7** was heated at 80 °C for 0.5 h under an Argon atmosphere to give the corresponding coupling product **5** in 84% yield (entry 6). Prolonged reaction time gave no further improvement in the yield (entries 7 and 8). Recently, microwave has come to be used as an efficient heating procedure.⁶ A microwave-assisted Suzuki coupling reaction was described by Sharma et al.,⁷

ABSTRACT

A potent antiinflammatory methyl picolinate alkaloid CJ-14877 [(+)-1] and its enantiomer (–)-1 were synthesized in two steps starting from commercially available methyl 5-bromopicolinate. The synthesis includes microwave-assisted *Suzuki* coupling reaction and *Sharpless* asymmetric dihydroxylation. © 2009 Elsevier Ltd. All rights reserved.

which we applied to the present scheme. When the reaction mixture was heated by means of microwave at 140 °C for 5 min, the reaction proceeded to give the corresponding coupling product **5** in 87% yield (entry 15).⁸ When (*Z*)-prop-1-enylboronic acid (**8**) was employed as the substrate, the coupling product **9** was obtained in 93% yield (entry 16). By the *Sharpless* asymmetric dihydroxylation (AD) of the coupling product **5** using AD-mix- α ,⁹ diol (+)-**1** was obtained in quantitative yield,¹⁰ whose spectral and physical data were identical to those of natural (+)-**1**. The



Figure 1. Natural cytokine production inhibitors CJ-14877 [(+)-1] and their analogues.



^{*} Corresponding author. Tel.: +81 426 76 3007; fax: +81 426 77 1436. *E-mail address:* takeyak@ps.toyaku.ac.jp (K. Takeya).

⁰⁹⁶⁰⁻⁸⁹⁴X/\$ - see front matter \odot 2009 Elsevier Ltd. All rights reserved. doi:10.1016/j.bmcl.2009.02.064



Scheme 1. Synthetic strategy for preparation of (+)-1 and its enantiomer (-)-1 from **6**.



Scheme 2. Asymmetric dihydroxylation of 5.

enatiomeric excess of this product was calculated by using the chiral column OD-HPLC system and was shown to be 97% ee.¹¹

Table 1

Palladium-mediated coupling reactions of methyl 5-bromopicolinate ($\mathbf{6}$) with (E)- or (Z)-prop-1-enylboronic acids ($\mathbf{7}$ or $\mathbf{8}$)



Entries ^a	Boronic acids (3.0 equiv)	Reaction temp (°C)	Reaction time (h)	Products	Yields (%)
1	7	rt	5	5	70 (12) ^b
2	7	rt	24	5	65 (15) ^b
3	7	50	1	5	58 (28) ^b
4	7	50	5	5	87
5	7	50 (MW) ^c	5 min	5	20 (61) ^b
6	7	80	0.5	5	84
7	7	80	1	5	85
8	7	80	5	5	85
9	7	80 (MW) ^c	5 min	5	43 (46) ^b
10	7	80 (MW) ^c	$5 \text{ min} \times 2$	5	53 (26) ^b
11	7	120 (MW) ^c	5 min	5	73 (20) ^b
12	7	120 (MW) ^c	10 min	5	88 (5) ^b
13	7	120 (MW) ^c	$5 \min \times 2$	5	87
14	7	130 (MW) ^c	5 min	5	80 (5) ^b
15	7	140 (MW) ^c	5 min	5	87 (1) ^b
16	8	140 (MW) ^c	5 min	9	93

^a Ref. 8.

^b The yields in parenthesis means the recovery of the starting material.

^c MW: microwave irradiation.

IL-1 β production inhibitory activity (%) induced with LPS

Compounds	Concentration (µM)				
	0.01	0.1	1.0	10	
(+)-1	-9.5	13.8	39.6	49.8	
(-)-1	9.1	4.3	10.6	-7.5	



Figure 2. Effect of (+)-1 and its enantiomer (–)-1 on IL-1 β production induced with LPS (100 ng).

When AD-mix- β^9 was employed as an oxidant in the dihydroxylation reaction of **5**, instead of AD-mix- α , the enatiomer (–)-**1** was obtained also in very high yield and with very high enantiomeric excess (Scheme 2).

The both of CJ-14877 [(+)-1] and its enantiomer [(–)-1] were evaluated for inhibitory activities of LPS-stimulated IL-1 β production by human PBMC.¹² The results was shown in Table 2 and Figure 2. CJ-14877 [(+)-1] inhibited IL-1 β production depending

on the substrate level and the inhibition ratio was 49.8% at 10 μ M. On the other hand, its enantiomer [(–)-1] showed no IL-1 β production inhibitory activity at 10 μ M. That indicated that the stereochemistry on C-7 and C-8 of compound 1 are important on the activity.

In summary, an effective and facile two step synthesis of CJ-14877 ((+)-1) and its enantiomer [(-)-1] from commercially available methyl 5-bromopicolinate (6) was successfully established for the first time. Preparation of a series of synthetic analogues is now in progress.

Acknowledgments

This work was supported by a Grant-in-aid for Scientific Research (C) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan.

References and notes

- Ichikawa, K.; Hirai, H.; Ishiguro, M.; Kambara, T.; Kato, Y.; Kim, Y. J.; Kojima, Y.; Matsunaga, Y.; Nishida, H.; Shiomi, Y.; Yoshikawa, N.; Kojima, N. J. Antibiot. 2001, 54, 703.
- 2. Isaka, M.; Palasarn, S.; Sriklung, K.; Kocharin, K. J. Nat. Prod. 2005, 68, 1680.
- 3. Kolb, H. C.; VanNieuwenhze, M. S.; Sharpless, K. B. Chem. Rev. 1994, 94, 2483.
- 4. Suzuki, A. Chem. Commun. 2005, 4759. and the references cited therein..
- Methyl 5-bromopicolinate (5) was purchased from Combi-Blocks Co. (Cat. No. CA-4117). The starting material can also be prepared by the procedure reported by Song et al. (J. Org. Chem. 2001, 66, 605.).
- Lidström, P.; Tierney, J.; Wathey, B.; Westman, J. Tetrahedron 2001, 57, 9225. and the references cited therein.
- Sharma, A. K.; Gowdahalli, K.; Krzeminski, J.; Amin, S. J. Org. Chem. 2007, 72, 8987.
- General procedure for microwave-assisted Suzuki coupling reaction: A mixture of methyl 5-bromopicolinate (0.02 g, 0.093 mmol), (E)-prop-1-enylboronic acid (0.023 g, 0.28 mmol), Pd(PPh₃)₄ (0.01 g, 0.0093 mmol), K₂CO₃ (0.039 g,

0.28 mmol), and dry DMF (1.0 mL) was heated at 140 °C by using a microwave apparatus (at 2.45 GHz, Discover, CEM Co., North Carolina, USA) for 5 min. After dilution with H₂O (10 mL), the mixture was extracted with AcOEt (10 mL × 3), and the extract was washed with H₂O (10 mL × 3), dried over MgSO₄, filtered, and evaporated in vacuo to give an oily residue, which was purified by MPLC (hexanes:AcOEt = 1:2). The yield of the resulting coupling product **5** was 85%. Compound **5**: Colorless amorphous solid, mp 67–68 °C (MeOH). ¹H NMR (400 MHz, CDCl₃) δ 861 (1H, d, 2.0), 8.02 (1H, d, 8.2), 7.71 (1H, dd, 8.2, 2.0), 6.48–6.36 (2H, m), 3.96 (3H, s), 1.91 (3H, d, 5.0). ¹³C NMR (100 MHz, CDCl₃) δ 165.6 (s), 147.6 (d), 145.6 (s), 136.6 (s), 132.9 (d), 131.3 (d), 126.8 (d), 125.0 (d), 52.7 (q), 18.7 (q). IR (film): v_{max} 1738 (C=O), 1708 (C=C) cm⁻¹. HRMS (ESI): Calculated for C₁₀H₁₂NO₂ (M⁺+H): 178.0868. Found: 178.0860. Compound **9**: Colorless viscous oil. ¹H NMR (125 MHz, CDCl₃) δ 165.7 (s), 150.0 (d), 145.4 (s), 136.7 (s), 136.4 (d), 131.6 (d), 125.6 (d), 124.7 (d), 52.8 (d), 145.0 (g), 148.7 (g), 116.7 (g), 1721 (C=C) cm⁻¹. HRMS (ESI): Calculated for C₁₀H₁₂NO₂ (m⁺+H): 178.0868. Found: 178.0868. Found: 178.0868. Found: 178.0869.

- 9. AD-mix-α and -β (Cat. No. 392758-10G and 392766-10G) were purchased from Aldrich Co. (MI).
- 10. General procedure for Sharpress asymmetric dihydroxylation: A mixture of compound 5 (0.03 g, 0.169 mmol), AD-mix-α (0.237 g, 0.169 mmol), and AcNH₂ (0.016 g, 0.169 mmol) in 'BuOH-H₂O (1:1, 2.1 mL) was stirred at room temperature for 6 h. After addition of satd Na₂SO₃ (10 mL), the mixture was extracted with AcOEt (10 mL × 3), and the extract was dried over MgSO₄, filtered, and evaporated in vacuo to give an oily residue, which was purified by MPLC (CHCl₃/MeOH = 15:1) to give (+)-1 in a quantitative yield. The spectral and physical data of the product were identical to those of natural CJ-14877 reported by Ichikawa et al.¹
- 11. The percentage of enantiomeric excess (% ee) values of (+)- and (-)-1 were calculated on the basis of HPLC analysis. (Analytical conditions: column: CHIRALCEL OD-H (Daisel Co., Ltd, 0.46 × 15 cm), elution: *n*-hexane-ⁱPrOH (85:15), at flow rate of 0.6 mL/min, detection: UV (270 nm)). Retention time (*t*_R): 29.0 min for [(+)-1]; 33.6 min for [(-)-1].
- 12. Human peripheral blood mononuclear cells (PBMC) in RPMI1640 medium containing 10% fetal bovine serum were cultured with various concentration of the compounds in the presence of 100 ng/ml lipopolysaccharides (LPS, *E. coli* B4) for 24 h. The human IL-1β concentration in the culture supernatant was measured by ELISA in accordance with the protocol of the manufacturer (eBioscience, Inc.).